Pharmacologic interventions for reversing the effects of oral anticoagulants

American Journal of Health-System Pharmacy

Volumn 70, Issue 10 SUPPL.1, 2013, Pages

  Kalus, James S ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; BERIPLEX P N; BLOOD CLOTTING FACTOR 9 COMPLEX; COFACT; DABIGATRAN; FEIBA NF; FRESH FROZEN PLASMA; KANOKAD; NOVOSEVEN RT; PHYTOMENADIONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CORONARY ARTERY BYPASS SURGERY; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EMERGENCY TREATMENT; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LOW DRUG DOSE; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS;

EID: 84878301573     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130041     Document Type: Article

References (51)

1. Ageno W, Gallus AS, Wittkowsky A et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(Suppl2):e44S-88S.
2. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence- based clinical practice guidelines. Chest. 2012; 141(Suppl 2):e152S-84S.
3. Neel S. Essential warfarin knowledge. In: Gulseth M, ed. Managing anticoagulation patients in the hospital. Bethesda, MD: American Society of Health-System Pharmacists; 2007:133-75.
4. Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting. Ann Pharmacother. 2012; 46:1617-26.
5. Gunther KE, Conway G, Leibach L et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res. 2004; 113:205-9. (Pubitemid 38609405)
6. Crowther MA, Garcia D, Ageno W et al. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: results of a prospective cohort study. Thromb Haemost. 2010; 104:118-21.
7. Fresh frozen plasma (blood component)- FFP. Medscape reference. http://reference.medscape.com/drug/ffp-fresh-frozen-plasma- 99499 (accessed 2013 Jan 4).
8. DomBourian M, Holland L. Optimal use of fresh frozen plasma. J Infus Nurs. 2012; 35:28-32.
9. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol. 2008; 25:784-9.
10. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health-Syst Pharm. 2012; 69:1473-84.
11. NovoSeven RT (coagulation factor VIIa [recombinant]) prescribing information. Princeton, NJ: Novo Nordisk Inc; 2012 Jan. www.novo-pi.com/ novosevenrt.pdf (accessed 2013 Jan 4).
12. Bebulin (factor IX complex) prescribing information. Westlake Village, CA: Baxter Healthcare Corporation; 2011 Apr. www.baxter.com/downloads/ healthcare-professionals/products/bebulin-vh-pi.pdf (accessed 2013 Jan 4).
13. Profilnine SD (factor IX complex) prescribing information. Los Angeles, CA: Grifols Biologicals Inc; 2011 Aug. www.grifolsusa.com/Controller?-fb= pfch&pAction =-factory&file=profil9-ft.pdf&-fp=0&idPortlet= 15341&idval=385714 (accessed 2013 Jan 4).
14. Beriplex P/N summary of product characteristics. Marburg, Germany: CSL Behring; 2011 Jul. www.medicines. org.uk/EMC/medicine/21147/SPC/ Beriplex+P+N+250+%26+500+IU/ (accessed 2013 Jan 4).
15. Kanokad summary of product characteristics. Paris, France: LFB-Biomedicaments; 2009 Feb. www.has-sante.fr/portail/upload/docs/application/ pdf/2011-03/kanokad-ct-6278.pdf (accessed 2013 Jan 4).
16. FEIBA NF (anti-inhibitor coagulant complex, nanofiltered and vapor heated) prescribing information. Westlake Village, CA: Baxter Healthcare Corporation; 2011 Feb. www.baxter.com/downloads/healthcare-professionals/ products/feiba-nf-pi.pdf (accessed 2013 Jan 4).
17. Sarode R, Matevosyan K, Bhagat R et al. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg. 2012; 116:491-7.
18. Holland L, Warkentin TE, Refaai M et al. Suboptimal effect of a threefactor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009; 49:1171-7.
19. Boulis NM, Bobek MP, Schmaier A et al. Use of factor IX complex in warfarinrelated intracranial hemorrhage. Neurosurgery. 1999; 45:1113-8.
20. Chapman SA, Irwin ED, Beal AL et al. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother. 2011; 45:869-75.
21. Joseph B, Amini A, Friese RS et al. Factor IX complex for the correction of traumatic coagulopathy. J Trauma Acute Care Surg. 2012; 72:828-34.
22. Song MM, Warne CP, Crowther MA. Prothrombin complex concentrate (PCC, Octaplex) in patients requiring immediate reversal of vitamin K antagonist anticoagulation. Thromb Res. 2012; 129:526- 9.
23. Sarode R, Milling TJ, Refaai MA et al. Integrated safety analysis of a 4-factor prothrombin complex concentrate versus plasma in phase III clinical trials. Poster presented at Thrombosis and Hemostasis Summit of North America, Chicago, IL: May 3-5, 2012. http://cdn.f1000.com/posters/docs/249931755 (accessed 2013 Jan 4).
24. CSL Behring news release. CSL Behring data shows 4-factor prothrombin complex concentrate is as effective and a more rapid treatment for vitamin K antagonist reversal than current standard of care. May 4, 2012. www.cslbehring.com/s1/cs/enco/1151517263302/news/1255928833642/prdetail.htm (accessed2013 Jan 4).
25. Khorsand N, Veeger NJ, Muller M et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Transfus Med. 2011; 21:116-23.
26. Lubetsky A, Hoffman R, Zimlichman R et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004; 113:371-8. (Pubitemid 38844367)
27. Pabinger I, Brenner B, Kalina U et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008; 6:622-31. (Pubitemid 351404929)
28. Preston FE, Laidlaw ST, Sampson B et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002; 116:619-24. (Pubitemid 34178663)
29. Nishijima DK, Dager WE, Schrot RJ et al. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med. 2010; 17:244-51.
30. Pinner NA, Hurdle AC, Oliphant C et al. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg. 2010; 74:631-5.
31. Wójcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarininduced coagulopathy. Int J Emerg Med. 2009; 2:217-25.
32. Cartmill M, Dolan G, Byrne JL et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000; 14:458-61.
33. Fredriksson K, Norrving B, Strömblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992; 23:972-7.
34. Huttner HB, Schellinger PD, Hartmann M et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006; 37:1465-70. (Pubitemid 44305727)
35. Makris M, Greaves M, Phillips WS et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997; 77:477-80. (Pubitemid 27121012)
36. Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011; 42:3594-9.
37. Godier A, Miclot A, Le Bonniec B et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012; 116:94-102.
38. Van Ryn J, Ruehl D, Priepke H et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica. 2008; 93(s1):148.Abstract 0370. http://online.haematologica.org/eha13/browserecord. php?-action=browse&-recid=1923 (accessed 2013 Jan 4).
39. Gruber A, Marzek UM, Buetehorn U et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood. 2008; 112:abstract 3825. http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/3825? maxtoshow=&hits=10&RESULTFORMAT=&fulltext=gruber&searchid= 1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT (accessed 2013 Jan 4).
40. Blombäck M, He S, Bark N et al. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol. 2001; 152:758-65.
41. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation. 2011; 124:1573-9.
42. Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108:217-24.
43. Dager WE, Roberts AJ. Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. [Epub ahead of print] 2013 Mar 7.
44. Warkentin TE, Margetts P, Connolly SJ et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012; 119:2172-4.
45. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract. [Epub ahead of print] 2012 Nov 16.
46. Stangier J, Rathen K, Stahle H et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-center study. Clin Pharmacokinet. 2010; 49:259-68.
47. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-27.
48. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health-Syst Pharm. 2008; 65:1520-9.
49. Kubitza D, Becka M, Mueck W et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010; 70:703-12.
50. Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87(Suppl 1):S141-5.
51. Eliquis (apixaban) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. 2012 Dec. http://packageinserts.bms.com/pi/pi-eliquis.pdf (accessed 2013 Jan 4).